Effects of Human Urinary Kallidinogenase on Early Improvement and Functional Outcomes in Acute Ischemic Stroke (TK-SPEED)

Official title

Effects of Human Urinary Kallidinogenase on Early Improvement and Functional Outcomes in Acute Ischemic Stroke: a Multicenter, Randomized, Open Label, Blinded-endpoint, Controlled Study (TK-SPEED)

Overview

The primary purpose of this trial is to evaluate the effects of Human Urinary Kallidinogenase on improvement of neurological outcome, and early cerebral perfusion in acute ischemic stroke.

Detailed description

This is a multicentre, randomized, open label, blinded-endpoint trial that aims to investigate the effects of Human Urinary Kallidinogenase treatment on neurological outcomes, early cerebral perfusion in patients with acute anterior circulation ischemic stroke. Patients in intervention group will be given 0.15 peptide nucleic acids (PNA) Human Urinary Kallidinogenase concentrated solution for intravenous injection once a day for 10 days continuously, and those in the control group will be given conventional therapy. Both groups of patients will be on standard stroke care. In this study, patients who were eligible to the inclusion criteria and ineligible to the exclusion criteria will be randomly assigned into two groups by a 1:1 ratio after the informed consent form (ICF) was received. The total sample size will be 540. All patients will be followed up for 90 days. The primary outcome is the proportion of modified Rankin Scale 0-2. Besides, the investigators aimed to use computed tomography perfusion (CTP) evaluate the differences of ischemic penumbra volume and regional cerebral blood flow (rCBF) before and after treatment between intervention group and control group.

Furthermore, this study adopts adaptive design, prospectively stating interim analyses with specified stopping rules, which allow for the possibility of the study to terminate early based on either determination of study success or of the futility to continue further enrollment.

Interventions

• Drug Human Urinary Kallidinogenase
  Intravenous injections of urinary kallidinogenase (0.15 peptide nucleic acids (PNA) in 0.9% NaCl) intravenous drip QD for 10 days.
• Other Clinical Routine Treatment
  Conventional therapy of acute ischemic stroke after based on Chinese guidelines

Primary outcome measures

• The proportion of patients with modified Rankin Scale (mRS) 0-2 at day 90 [Time frame: 90 days]

Secondary outcome measures (6)

• Change of Tmax>6s volume [Time frame: 5 days]
• Change of rCBF in Tmax>6s area [Time frame: 5 days]
• Ordinal distribution of modified Rankin Scale (mRS) at day 90 [Time frame: 90 days]
• The proportion of patients with modified Rankin Scale (mRS) 0-1 at day 90 [Time frame: 90 days]
• Change of National Institute of Health stroke Scale (NIHSS) score at day 5 after treatment. [Time frame: 5 days]
• Change of National Institute of Health stroke scale (NIHSS) score at day 10 after treatment. [Time frame: 10 days]

Eligibility criteria

Inclusion criteria

• 18 to 80 years of age;
• Diagnosis of anterior circulation acute ischemic stroke;
• Within 48 hours of symptoms onset;
• modified Rankin Scale (mRS) score≤1 before this event;
• 5≤NIHSS≤20 at screening;
• The availability of informed consent.

Exclusion criteria

• Patients who have already or are going to receive intravenous thrombolytic/mechanical thrombectomy therapy after onset;
• Patients with severe consciousness disorder, NIHSS 1a consciousness level score≥2;
• Patients with limited limb mobility such as fractures and claudication upon admission;
• Patients who have already or are going to receive Edaravone injection, Edaravone and DeKanol concentrated solution for injection, Butylphthalide and sodium chloride injection or Butylphthalide soft capsules after onset;
• Hypotensive (systolic blood pressure <90 mmHg or diastolic blood pressure<60 mmHg) on admission;
• History of severe drug or food allergy, allergy or intolerance to Human Urinary Kallidinogenase;
• Patients who have been on angiotensin-converting enzyme inhibitor (ACEI) drugs and within 5 half-lives (according to the specific drug instructions) before initiate Human Urinary Kallidinogenase treatment;
• Pregnancy, lactation, or planned pregnancy within 90 days;
• Patients with severe renal failure or impairment (eGFR<30ml/min/1.73m2) at screening;
• Severe hepatic dysfunction, elevation of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) (more than 2.5 times of upper limit of normal value), other liver diseases such as acute and chronic hepatitis, cirrhosis, etc;
• Patients with heart failure (NYHA class III or IV), unstable angina pectoris, acute myocardial infarction, severe arrhythmia, and degree II and III cardiac conduction obstruction within 6 months prior to randomization;
• Heavy drinking in the three months before screening, drinking≥5 standard drinks per day (1 standard drink is equivalent to120ml wine, 360ml beer or 45ml liquor);
• Drug Abuse or addiction in the past year;
• Patients with a malignant tumor, severe systemic diseases, or estimated survival time <90 days;
• Patients with severe mental disorders or dementia unable to complete the informed consent and follow-up;
• Have participated in another interventional clinical study within 30 days before randomization or are participating in another interventional clinical study;
• Other cases unsuitable for this clinical study assessed by researcher.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Single blind

Primary purpose

Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT06132880 · KLK-S024

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗